Clinical Trial Update: A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) [Phase 1, Phase 2]

View source ↗

Summary

A rollover protocol update is described to allow continued access to the LSD1 inhibitor seclidemstat (SP-2577) in ongoing Phase 1/Phase 2 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiomatoid Fibrous Histiocytoma
• Clear Cell Sarcoma
• Desmoplastic Small Round Cell Tumor
• Ewing Sarcoma
• Extraskeletal Myxoid Chondrosarcoma
• Low Grade Fibromyxoid Sarcoma
• Myoepithelial Tumor
• Myxoid Liposarcoma
• Sclerosing Epithelioid Fibrosarcoma

Drugs mentioned

• Seclidemstat (seclidemstat)

Snippet

Sponsor: Salarius Pharmaceuticals, LLC | Conditions: Ewing Sarcoma, Myxoid Liposarcoma | Phase 1, Phase 2 | Status: UNKNOWN